A Scalable Adenovirus Production Process From Cell Culture To Purified In our tutorial series on viral vector production, ge scientists share their insights on virus production and how to tackle viral vector manufacturing challenges. in one episode a. Based on the cap™ cell line, the cap ad cell line offers scalable, high yield production of adenovirus particles ― while minimizing replication competent adenovirus (rca). this producer cell line is well suited for adenovirus production for gene therapy or vaccine applications.
Viral Vector Production Unit Upv Ge healthcare proposes a novel process for adenovirus production, one that compares well with a reference process in terms of virus load capacity, recovery, and purity. In this study, we have combined technical evaluation of process steps and process economy calculations, from adv production in cell culture to purified bulk product in up to 10 l scale (1–8). human adv5, expressing the green fluorescent protein (gfp), was used for process development. Adenovirus (ad) vector based vaccines can be manufactured and stockpiled in large quantities at a short notice inexpensively with cell culture based technology without the need for enhanced biosafety facilities. Various adenovirus (adv) vector systems have proven to be lucrative options for gene delivery. they can serve as potential vaccine candidates for prevention of several common infectious diseases and hold the promise for gene therapy, especially for cancer.
A Scalable Adenovirus Production Process From Cell Culture To Purified Adenovirus (ad) vector based vaccines can be manufactured and stockpiled in large quantities at a short notice inexpensively with cell culture based technology without the need for enhanced biosafety facilities. Various adenovirus (adv) vector systems have proven to be lucrative options for gene delivery. they can serve as potential vaccine candidates for prevention of several common infectious diseases and hold the promise for gene therapy, especially for cancer. Multiple scalable systems have now been developed for the production of raav, including adenovirus based, baculovirus based, and rhsv based methods (aucoin et al., 2008). the most significant innovation in raav manufacture in recent years is the advent of baculovirus infection of insect cells. Process results in an adenovirus preparation comparable to clinical grade products, with high yield and very low host cell protein (hcp) and dna contamination. it is readily scalable, simple, rapid, and efficient and thus well suited for the production of clinical grade viral vectors. Manufacturing of safe and efficacious clinical grade virus relies on a scalable and cost effective production process. in this study, we have combined experimental work and process economy calculations, from adv production in cell culture to purified bulk product up to 10l scale.
A Scalable Adenovirus Production Process From Cell Culture To Purified Multiple scalable systems have now been developed for the production of raav, including adenovirus based, baculovirus based, and rhsv based methods (aucoin et al., 2008). the most significant innovation in raav manufacture in recent years is the advent of baculovirus infection of insect cells. Process results in an adenovirus preparation comparable to clinical grade products, with high yield and very low host cell protein (hcp) and dna contamination. it is readily scalable, simple, rapid, and efficient and thus well suited for the production of clinical grade viral vectors. Manufacturing of safe and efficacious clinical grade virus relies on a scalable and cost effective production process. in this study, we have combined experimental work and process economy calculations, from adv production in cell culture to purified bulk product up to 10l scale.
Comments are closed.